Abstract
The most common demyelinating disease is multiple sclerosis, and for the disease for which there is no curative treatment, there are only treatments used to reduce the frequency of attacks and symptoms. Fingolimod, one of the most important of these, is an immunomodulatory drug that acts as a sphingosine-1 phosphate receptor regulator and has many side effects. Nanoparticle-based drug delivery systems are modified as desired and given to the body, the dose and release time can be controlled. Sodium alginate is a biocompatible polysaccharide and preferred in nanoparticle formulations for drug delivery systems. It is aimed to encapsulation of fingolimod in alginate nanoparticles to reduce side effects and increase its effectiveness on membrane damage induced Human U-87 MG Glioma Cells. Nanoparticles with an average size of 106 nm were obtained by encapsulating Fingolimod with sodium alginate polymer and characterized by Dynamic Light Scattering (DLS), Scannig Electron Microscope (SEM), Atomic Force Microcope (AFM) and Fourier-Transform Infrared Spectroscopy (FTIR) analysis. Membrane damage was induced using lysophosphatidylcholine on the U-87 MG cell line. In order to demonstrate the efficacy of Fingolimod loaded sodium alginate nanoparticles on cells, cytotoxicity, neuroproliferative effect, neuroregenerativeness and neuroprotectivity analysis, apoptotic effect, cell migration, and cellular uptake were demonstrated. Within the scope of the study, the effectiveness of Fingolimod loaded sodium alginate nanoparticles, which have not been studied before in the literature, were examined and it was concluded that in addition to the limited symptomatic effects of Fingolimod mentioned in the literature, it also showed neuroregenerative, neuroprotective and neuroproliferative effects at the cellular level. This efficiency of Fingolimod has been increased by encapsulation of sodium alginate nanoparticles and has been studied at a level that can be a basis for future studies.